This post was originally published on this site
AEZS’ shares have surged 44.2% year-to-date, fueled by the company’s efforts to advance the development of its AIM Biologicals pre-clinical program. But the stock plummeted 15.7% over the past month and 30.3% over the past three months, reflecting investor concerns over its non-compliance with the Nasdaq listing rules and fears of potential delisting.
Closing yesterday’s session at $0.61, the stock is trading 83.1% below its 52-week high of $3.62. The company’s underwhelming financials could cause its shares to witness a pullback soon. Moreover, its potential orally active COVID-19 vaccine is still in its preclinical development planning stage. So, the revenue-generating prospects from the drug remain uncertain.
